SlideShare a Scribd company logo

PMDT Guidelines and management strategies

Download as PPTX, PDF
N
nishumbbs8099499206

The document outlines the management and treatment regimens for multi-drug resistant tuberculosis (MDR-TB) and highlights the new WHO recommendations regarding the BPAL regimen, including its efficacy and usage guidelines under operational research conditions. It provides detailed information on dosages, duration of treatments, and the management of adverse drug reactions associated with various TB medications. Moreover, it emphasizes the need for careful monitoring during treatment, especially for specific patient populations such as those with HIV or extensive disease.

Education
1 of 55
Download to read offline
1
2
3
Most read
4
Most read
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
PMDT PART 2 Dr. G Nishanth Kumar Junior Resident Resp.Medicine,PIMS
INDEX •BPal regimen •(H) mono/poly DR-TB regimen •Adverse drug events •Management of adverse drug events
BPal regimen • Bedaquiline, Pretomanid, Linezolid (BPaL) regimen • Useful for MDR-TB with additional FQ resistance • New WHO recommendations • A treatment regimen lasting 6-9 months, composed of Bedaquiline, pretomanid and linezolid (BPaL) may be used under operational research conditions in MDR-TB patients with TB that is resistant to fluoroquinolones, who have either no previous exposure to Bedaquiline and linezolid or have been exposed for no more than 2 weeks; and • This is a new recommendation for a defined patient group; it is to be used under operational research conditions, and thus does not apply to routine programmatic use.
• Evidence (Conradie F, et al NEJM. 2020 Mar 5;382(10):893-902 (Nix TB trial)): BPaL showed 90% favourable outcomes among XDR (89%), MDR with FQ resistance, treatment intolerant /non responders (92%); • Peripheral neuropathy 81%, myelosupression 48%, all managed often with dose reductions or interruptions in treatment with linezolid. Dosage & duration • Pretomanid - 200 mg once daily for 26 weeks, Bedaquiline - 400 mg once daily for the first 2 weeks of treatment (days 1–14) and then 200 mg three times a week for 24 weeks, and linezolid - 1200 mg once daily for 24 weeks (after 1 month, dose and duration modification for linezolid is permissible), with an option to extend treatment to 39 weeks if they were culture-positive at week 16.
NTEG recommendation • BPaL research proposal may be considered with flexibility to adapt with anticipated results of ZeNix trial with 4 arms of reduce dosage and duration of Linezolid in BPaL; • and In exceptional cases, BPaL can be considered as a last resort by NTEP under prevailing ethical standards in individual patients for whom the design of an effective regimen is not possible as per WHO recommendations
Implementation considerations • Pretomanid is approved by DCGI for use as part of BPaL regimen for conditional access under NTEP;In exceptional cases where an effective longer oral M/XDR-TB regimen cannot be designed with available drugs, NDR-TBC/state DT3C may send their case to national DT3C for clinical decision support and recommendations for BPaL; • Initial hospitalization for 15 days at NDR-TBC ward is necessary to closely monitor tolerability;
(H) mono/poly DR-TB regimen • Once the patient is found to be rifampicin sensitive, the second specimen available must be sent immediately by the NAAT technician to the C&DST laboratory for FL-LPA test • The patient is immediately initiated on standard regimen for DS-TB by the concerned CHO at HWC/ health facility doctor or private health- care provider. • If H resistance is not detected, the patient will be continued on DS TB regimen and monitored for response to treatment.
• If H resistance is detected on FL-LPA (serves as a surrogate of first-line poly resistance as per NDRS), the LPA deposit must be subjected to SL-LPA and LC&DST to Mfx, Z, Lzd, Cfz* and the test result must simultaneously be uploaded by a microbiologist at the C&DST lab on Nikshay • If H mono/poly DR-TB is detected, appropriate clinical evaluation is conducted by the treating doctor and H mono/poly DR-TB regimen is initiated at the respective health facility itself while waiting for the results of SL-LPA and LC&DST
• As soon as the results of SL-LPA and LC&DST are available, the treating doctor may need to modify the regimen using the replacement sequence detailed later in the event of additional resistance or intolerance or non-availability of any drug in use or emergence of exclusion criteria • At any time during the treatment with DS-TB or H mono/poly DR-TB regimen with or without modifications, if there are signs of non- response, the patient must be subjected to NAAT again to rule out amplification of rifampicin resistance and further LPA and DST at specific time points
PMDT Guidelines and management strategies
Pre-treatment evaluation Pre-treatment evaluation for any TB patient must include a thorough clinical evaluation by a doctor with History and physical examination 1. Height/weight 2. Random blood sugar (RBS) 3. Chest X-ray 4. HIV test • No additional investigations are required for H mono/poly DR-TB patients unless clinically indicated
H mono/poly DR-TB regimen (R resistance not detected & H resistance detected) under NTEP: • H mono/poly DR-TB regimen is of 6 or 9 months with no separate IP/CP. • In exceptional situations of unavailability of loose drug R or E or Z, the use of 4 FDC (HREZ) with Lfx loose tablets may be considered as an option rather than not starting the H mono/poly DR-TB patients on treatment.
Treatment extension • Total duration of H mono/poly DR-TB regimen is 6 months. It can be extended directly to 9 months in certain conditions. • In patients with extensive disease; uncontrolled comorbidity; extra- pulmonary TB; if smear at the end of month 4 is found positive and when regimen is modified, the treatment may be directly extended to 9 months. There would be no monthly extensions in this regimen. • In patients who remain sputum smear positive at the end of month 5 or later, the treatment outcome will be declared as ‘treatment failed’ and the patient will be re-evaluated as per the diagnostic algorithm as a non-responder
REPLACEMENT SEQUENCE • Treatment duration of H mono/poly DR-TB regimen can be longer in extensive pulmonary TB diseases up to 9 months
FOLLOW UP EVALUATION
PMDT Guidelines and management strategies
• The most important evidence of response to DR-TB treatment is conversion of sputum smear and culture to negative. • Good quality sputum specimen is therefore essential to get reliable results that form the basis of monitoring bacteriological response to treatment. • It must be noted that the final treatment outcome of H mono/poly DR-TB patients will be declared based on follow up culture results.
• NAAT, FL LPA, SL LPA (R, Eto, Lfx, Mfx) on fresh specimen and LC&DST (Mfx, Z, Lzd, Cfz*) (*whenever available) will be set up on the LPA deposits only for if patient remains smear/culture positive at end of month 4 and beyond if the patient has not reached bacteriological reversion. • If any change is required in the composition of H mono/poly DR-TB regimen due to the reason like resistance, intolerability, unavailability or contraindication during initial 4 months of treatment, re- initiation or re-registration is not required and patient will be continued • Long-term follow-up will be done with 6 monthly cultures among symptomatic patients till two years after completion of any DR-TB regimen i.e. months 6, 12, 18 and 24 post treatment.
SPECIAL SITUATIONS 1) Pregnancy & Lactation • In pregnant women, the H mono/poly DR-TB regimen may be started or continued. • In women of reproductive age, treated for H mono/poly DR-TB, the use of rifampicin may interacts with contraceptives, resulting in decreased efficacy of protection against pregnancy. 2) Patients with extensive disease • The prolongation of the H mono/poly DR-TB regimen to more than 6 months could be considered on an individual basis for patients with extensive disease up to a maximum of 12 months.
3) People living with HIV • The H mono/poly DR-TB regimen is recommended in HIV reactive TB patients. • In TB patients with HIV coinfection, the first priority is to ensure that they are started on ART within 8 weeks of TB treatment initiation (regardless of CD4 count). This applies to H mono/poly DR-TB patients as well. 4)Extra-pulmonary disease • The treatment of patients with extra-pulmonary TB should be designed in close consultation with appropriate specialists (e.g. infectious disease physicians and neurologists), to decide upon individual variations in treatment duration and supportive care as needed. • In CNS, skeletal and miliary TB, treatment may be given up to a year.
ADVERSE DRUG REACTIONS & THEIR MANAGEMENT
ADVERSE DRUG REACTIONS
1) QT PROLONGATION
PMDT Guidelines and management strategies
2)RASH, ALLERGIC REACTIONS & ANAPHYLAXIS • Suspected agent (s): Any drug • For minor dermatologic reactions, various agents can be helpful. In this case medication must be continued. • This could include antihistamines, hydrocortisone cream for localized rash, prednisone in a low dose of 10 to 20 mg per day for several weeks if other measures are not helpful and phototoxicity (may respond to sunscreens but can also cause rash).
• Dry skin may cause itching (especially in diabetics). In which case, a liberal use of moisturizing lotion is recommended, since dry skin is a common and significant problem with Cfz. • Once rash resolves, reintroduce remaining drugs, one at a time with the one most likely to cause the reaction last. The order of reintroduction will be H, Z, Eto, E, FQ. • For serious allergic reactions, it will be important to stop all therapies pending resolution of reaction and refer the patient to Nodal DR-TB centre/ tertiary centre for further management
3) (i)Gastrointestinal symptoms (nausea and vomiting) • Suspected agent(s): Eto, PAS, Z, E, Bdq • Initiate the following 3-step approach to manage nausea and vomiting: Step 1. Adjust medication and conditions without lowering overall dose. Give Eto at night; Eto or PAS twice or thrice daily; light snack (biscuits, bread, rice, tea) before medication; and PAS two hours after other anti-TB drugs. Step 2. Start antiemetic(s) like metoclopramide 10 mg, 30 minutes before anti- TB medication; Ondansetron 8 mg, 30 minutes before anti-TB drugs and again eight hours after. Ondansetron can either be used on its own or with metoclopramide (if ondansetron is not available, promethazine can be used). For refractory nausea give 24 mg, 30 minutes before the dose. Step 3. Decrease dose of suspected drug by one weight class (except Bdq and Dlm) if this can be done without compromising the regimen. It is rarely necessary to suspend the drug completely.
3)(ii) Gastrointestinal symptoms (gastritis & abdominal pain) • Suspected agent(s): PAS, Eto, Cfz, Lzd, FQs, H, E, and Z • if symptoms are associated and consistent with gastritis (epigastric burning or discomfort, sour taste in mouth associated with reflux) initiate medical treatment with the use of H2-blockers (ranitidine 150 mg twice daily or 300 mg once daily) better than proton-pump inhibitors (omeprazole 20 mg once daily) which should be avoided along with Bdq. • Avoid use of antacids as they decrease absorption of FQ; for severe abdominal pain, stop suspected agent(s) for short periods of time (1–7 days); lower the dose of the suspected agent, if this can be done without compromising the regimen; and discontinue suspected agent if this can be done without compromising the regimen
4)Hepatitis • Suspected agent(s): Z, H, R, Eto, PAS, Bdq
PMDT Guidelines and management strategies
5)Giddiness • Suspected agent (s) – Am, Eto, FQ and/or Z • Aminoglycosides, especially in elderly age group must be kept in mind for giddiness as it may be early sign of 8th nerve toxicity 6) Haematological abnormalities • Stop Lzd if myelosuppression (suppression of white blood cells, red blood cells or platelets) occurs. • Consider restarting with a lower dose of Lzd (300 mg instead of 600 mg) if myelosuppression resolves and if Lzd is considered essential to the regimen. • Consider nondrug related causes of hematological abnormality. • Consider blood transfusion for severe anemia.
7)Arthralgia • Suspected agent(s): Z, FQ, Bdq • Initiate with paracetamol in the beginning. • Treatment with nonsteroidal anti-inflammatory drugs (indomethacin 50 mg twice daily or ibuprofen 400 to 800 mg three times a day). • Lower the dose of the suspected agent (most commonly Z) if this can be done without compromising the regimen. • Discontinue the suspected agent if this can be done without compromising the regimen.
8)Peripheral neuropathy • Suspected agent(s): Lzd, Cs, H, Am, FQ, rarely Eto, E • To prevent occurrence of such adverse reaction, all patients on an NTEP regimen for MDRTB should receive daily pyridoxine. • The commonest offending agent is Lzd, almost 60–70% of the patients on Lzd 600 mg/day may develop neuropathy and pyridoxine does not help in preventing Lzd induced neuropathy. • Early recognition of neuropathy symptoms and early dose reduction of Lzd helps to prevent the progression. • If there is no improvement or symptoms worsen,amitriptyline 25mg will be added (to be avoided with Bdq) and if there is still no improvement, the patient should be referred to a neurologist; • correct any vitamin or nutritional deficiencies and maximum daily dose (100 mg/day);consider whether the dose of Cs can be reduced without compromising the regimen. If H is being used (especially Hh), consider stopping it
9)Depression, psychotic & suicidal ideation • Stop the suspected agent for a short period (1–4 weeks) while psychotic symptoms are brought under control. • The most likely drug is Cs followed Hh .If moderate to severe symptoms persist, initiate antipsychotic treatment (haloperidol).Hospitalize in a ward with psychiatric expertise if patient is at risk to himself/herself or others. • Lower the dose of the suspected agent (if it can be done without compromising the regimen).Discontinue suspected agent if this can be done without compromising the regimen
10)Seizures • Suspected agent(s): Cs, H, FQ • Hold Cs, FQ and H pending resolution of seizures. Initiate anticonvulsant treatment –carbamazepine, phenytoin or valproic acid (relatively safe with Bdq) are most commonly used. 11)Tendonitis and tendon rupture • Suspected agent(s): FQ • If significant inflammation of tendons or tendon sheaths occur, consider stopping FQ. • Give a non-steroidal anti-inflammatory drug (ibuprofen 400 mg four times daily).Rest the joint. • if treatment failed is likely without FQ: reduce dose if possible ensure joint is strictly rested inform patient of the possible risk of tendon rupture and discuss the risks and benefits of ongoing use of FQ
12) Nephrotoxicity (renal toxicity) • Suspected agent(s): Am • Discontinue the suspected agent. Consider using Cm if an aminoglycoside had been the prior injectable drug in the regimen. • Consider other contributing etiologies (non-steroidal anti- inflammatory drugs, diabetes, other medications, dehydration, congestive heart failure, urinary obstruction, etc.,) and address as indicated. • Follow creatinine (and electrolyte) levels closely, every 1–2 weeks.Consider dosing the injectable agent 2–3 times a week if the drug is essential to the regimen and the patient can tolerate (close monitoring of creatinine). • If creatinine continues to rise despite twice/thrice a week dosing, suspend the injectable agent.Adjust all TB medication according to creatinine clearance in consultation with nephrologist. • Also, note that renal impairment may be permanent.
13)Vestibular toxicity (tinnitus and dizziness) • Suspected agent(s): Am, Cs, FQs, H, Eto, Lzd • If early symptoms of vestibular toxicity appear, there may be a need to change dosing of the injectable agent to twice/thrice a week. • Also, consider using Cm if an aminoglycoside had been the prior injectable in the regimen. If tinnitus and unsteadiness worsen with the above adjustment, stop the injectable agent. • This is one of the few adverse events that may cause permanent intolerable toxicity and can necessitate discontinuation of a class of agents
14)Hearing loss • Suspected agent(s): Am • Common cause is aminoglycosides if the reason like wax and middle ear infection is ruled out. • Document hearing loss and compare with baseline audiogram if available (some degree of hearing loss occurs with most patients starting with high frequency loss). • If early symptoms of hearing loss are documented, change dosing of the injectable agent to twice/thrice a week. • Discontinue injectable agent if hearing loss continues despite dose adjustment and add additional drugs to reinforce the regimen. • Even when additional drugs are not available, stopping the injectable agent can be considered based on the patient’s desire to maintain hearing.
15) Optic neuritis • Suspected agent(s): E, Lzd, Eto, Cfz, H, S • Stop E and Lzd. Do not restart. • Refer patient to an ophthalmologist. 16)Metallic taste • Suspected agent(s): Eto, FQs • Suggested management strategy: Encourage the patient to tolerate this side effect.
17)Electrolyte disturbances- hypokalaemia and hypomagnesaemia • Suspected agent(s): Am • Evaluate potassium levels. • If potassium is low, check for magnesium and calcium (if unable to check for magnesium, consider empiric treatment with magnesium in all patients of hypokalaemia). • Replace electrolytes as needed. • Dose oral electrolytes apart from FQ as they can interfere with FQ absorption. • Manage electrolyte disturbances.
18)Gynaecomastia • Suspected agent(s): Eto • Breast enlargement can be a troublesome side effect of Eto treatment, especially for male patients. • Galactorrhoea has also been reported.Encourage patients to tolerate this side effect 19)Alopecia • Suspected agent(s):H, Eto • hair loss can occur or there can be significant thinning of the hair, but this is temporary and not progressive during treatment. • Encourage patients to tolerate this side effect.
20)Superficial fungal infection and thrush • Suspected agent(s): FQ • Topical antifungal agents or short course oral antifungal drugs are helpful. Exclude other diseases if response to treatment is not prompt (such as HIV). 21)Lactic acidosis • Suspected agent(s): Lzd • Suggested management strategy: Stop Lzd if lactic acidosis occurs
PMDT Guidelines and management strategies
PMDT Guidelines and management strategies
Treatment outcome of DR-TB Interim outcomes 1. Bacteriological conversion. After bacteriological confirmation of TB at least two consecutive cultures (applicable for DR-TB and DS-TB) or smears taken on different occasions at least 7 days apart (applicable for DS-TB only) are found to be negative. 2. Bacteriological reversion. At least two consecutive cultures (applicable for DR-TB and DSTB) or smears (applicable for DS-TB only) taken on different occasions at least 7 days apart are found to be positive either after the initial conversion or for patients without bacteriological confirmation of TB
FINAL OUTCOMES • Treatment failed. A patient whose treatment regimen needs to be terminated or permanently changed to a new regimen option or treatment strategy. • Cured. A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national policy with evidence of bacteriological response and no evidence of treatment failed.
• Treatment completed. A patient who completed treatment as recommended by the national policy whose outcome does not meet the definition for cure or treatment failed. • Died. A patient who died before starting or during the course of treatment. • Lost to follow-up. A patient who did not start treatment or whose treatment was interrupted for 2 consecutive months or more. • Not evaluated. A patient for whom no treatment outcome was assigned4
TPT among contacts of DR-TB patients
• WHO recommends TPT among contacts exposed to MDR-TB with FQ sensitive or H resistant with R sensitive DR-TB patients following consideration of intensity of exposure; confirming the source patient and her/his drug resistance pattern confirmed bacteriologically and ascertaining TBI using IGRA or TST. • Among contacts exposed to patients with known MDR-TB with FQ sensitive, WHO suggests the use of levofloxacin for six months (pediatric formulation for child contacts) if tolerated.
• If H susceptibility is confirmed in RR-TB index patients, contacts may be given 6H. • Among contacts exposed to individuals with known H-resistant TB with R sensitive, the use of rifampicin for four months is proposed. • Regardless of whether treatment is given or not, clinical followup should be done for two years and any emergent signs and symptoms suggestive of TB should be actively investigated and curative regimens started as needed.
PMDT Guidelines and management strategies
Policy for TPT in DR-TB contacts in India • Preventive treatment among HHC of MDR-TB index patients (in whom FQ resistance has been ruled out) and among HHC of H resistant index patients (in whom R resistance has been ruled out), the target population, using 6Lfx and 4R respectively to be introduced in a phased manner for all age groups to gain programmatic experience to guide future expansion while awaiting results of ongoing studies. • This recommendation may be considered for children given their special needs pan-India.
PMDT Guidelines and management strategies
PMDT Guidelines and management strategies
Thank You

More Related Content

PPTX
CAM presentation 2023.pptx
tila12nega
 
PPTX
Treatment of DS-TB.pptx for health care workers
arodiyamohammad78692
 
PPTX
Treatment of DS-TB.pptx for health care workers
arodiyamohammad78692
 
PPTX
WHO and RNTCP guidelines - Tuberculosis management
Dr. Pratyush Kumar
 
PPTX
Rntcp new guidelines
TAJAMUL LONE
 
PPTX
Recent changes in RNTCP Guidelines
Arvind Ghongane
 
PPTX
DRUG TREATMENT WITH Treatment of DR-TB.pptx
SUDHIRRAO46
 
PPTX
RS TB UPDATE.pptx
KrishRamakrishnan4
 
CAM presentation 2023.pptx
tila12nega
 
Treatment of DS-TB.pptx for health care workers
arodiyamohammad78692
 
Treatment of DS-TB.pptx for health care workers
arodiyamohammad78692
 
WHO and RNTCP guidelines - Tuberculosis management
Dr. Pratyush Kumar
 
Rntcp new guidelines
TAJAMUL LONE
 
Recent changes in RNTCP Guidelines
Arvind Ghongane
 
DRUG TREATMENT WITH Treatment of DR-TB.pptx
SUDHIRRAO46
 
RS TB UPDATE.pptx
KrishRamakrishnan4
 

Similar to PMDT Guidelines and management strategies (20)

PPTX
Shorter oral bedaquiline regimen 2022 NTEP guidelines
Ankur Gupta
 
PPTX
Management of TB 2019
Lifecare Centre
 
PPTX
Pmdt guidelines
rohit mahavarkar
 
PPTX
Its time
Praveen G S
 
PDF
REVISED NATIONAL TUBERCULOSIS CONTROL PROGRAME DAILY REGIMEN
Shivshankar Badole
 
PPTX
Rntcp update
Gyanshankar Mishra
 
PPTX
New guidelines for Tuberculosis treatment (NTEP)
SHOEBULHAQUE
 
PPTX
Pulmonary TB very common now and dys.pptx
MonaAzo
 
PPTX
Recent guidelines in the treatment of tuberculosis
SHOEBULHAQUE1
 
PDF
ntep-211118064113 (1).pdf
ShakibSheikh5
 
PPTX
NTEP
HarpreetKaur1291
 
PPTX
MO Induction tb ppt. in India recent update
Shraddha Patil
 
PPTX
MO Induction tb ppt. in India recent update
Shraddha Patil
 
PPTX
Recent Advances in Treatment of Drug Resistance Tuberculosis (1).pptx
drskmauryakgmu
 
PPT
Chinmoy tb presentation
Chinmoy Lath
 
PPTX
Tuberculosis treatment.pptx
Sushil Humane
 
PPT
Tuberculosis update
Sachin Verma
 
PPTX
what is new in tuberculosis
PathKind Labs
 
PPTX
MANAGMENT OF Tubercular preventive treatment
Kumar Utsav
 
PPT
management of tuberculosis adult cpg malaysia
luna439975
 
Shorter oral bedaquiline regimen 2022 NTEP guidelines
Ankur Gupta
 
Management of TB 2019
Lifecare Centre
 
Pmdt guidelines
rohit mahavarkar
 
Its time
Praveen G S
 
REVISED NATIONAL TUBERCULOSIS CONTROL PROGRAME DAILY REGIMEN
Shivshankar Badole
 
Rntcp update
Gyanshankar Mishra
 
New guidelines for Tuberculosis treatment (NTEP)
SHOEBULHAQUE
 
Pulmonary TB very common now and dys.pptx
MonaAzo
 
Recent guidelines in the treatment of tuberculosis
SHOEBULHAQUE1
 
ntep-211118064113 (1).pdf
ShakibSheikh5
 
NTEP
HarpreetKaur1291
 
MO Induction tb ppt. in India recent update
Shraddha Patil
 
MO Induction tb ppt. in India recent update
Shraddha Patil
 
Recent Advances in Treatment of Drug Resistance Tuberculosis (1).pptx
drskmauryakgmu
 
Chinmoy tb presentation
Chinmoy Lath
 
Tuberculosis treatment.pptx
Sushil Humane
 
Tuberculosis update
Sachin Verma
 
what is new in tuberculosis
PathKind Labs
 
MANAGMENT OF Tubercular preventive treatment
Kumar Utsav
 
management of tuberculosis adult cpg malaysia
luna439975
 
Ad

Recently uploaded (20)

PDF
Complications of Minimal Access Surgery at WLH
mohitsuren827
 
PPTX
human mycosis Human fungal infections are called human mycosis..pptx
shilpa939953
 
PDF
Yogi Goddess Pres Conference Studio Updates
LDMMia Reiki Lectures
 
PDF
Trump Administration's workforce development strategy
Mebane Rash
 
PDF
Anesthesia in Laparoscopic Surgery in India
mohitsuren827
 
PDF
Microbial disease of the cardiovascular and lymphatic systems
KeyaSharma
 
PDF
The Lost Whites of Pakistan by Jahanzaib Mughal.pdf
jahanzaibmughal6
 
PPTX
PPT- ENG7_QUARTER1_LESSON1_WEEK1. IMAGERY -DESCRIPTIONS pptx.pptx
KMDee
 
PPTX
Cell Types and Its function , kingdom of life
ClaireMangundayao1
 
PDF
Chinmaya Tiranga quiz Grand Finale.pdf
Nitin Suresh
 
PPTX
GDM (1) (1).pptx small presentation for students
shrawanbpkihs
 
PDF
A systematic review of self-coping strategies used by university students to ...
CleeveMoralde1
 
PPTX
Pharma ospi slides which help in ospi learning
rameetkumar304
 
PDF
Computing-Curriculum for Schools in Ghana
abigailanane203
 
PDF
Chapter 2 Heredity, Prenatal Development, and Birth.pdf
MarjorieLopezTiu
 
PDF
RTP_AR_KS1_Tutor's Guide_English [FOR REPRODUCTION].pdf
RobertMentino1
 
PDF
2.FourierTransform-ShortQuestionswithAnswers.pdf
Raji Murugan
 
PPTX
Orientation - ARALprogram of Deped to the Parents.pptx
JeromeTamayoSantiago1
 
PDF
STATICS OF THE RIGID BODIES Hibbelers.pdf
pascualasturiaskaye4
 
PPTX
Tissue processing ( HISTOPATHOLOGICAL TECHNIQUE
mathiasmelwyn7
 
Complications of Minimal Access Surgery at WLH
mohitsuren827
 
human mycosis Human fungal infections are called human mycosis..pptx
shilpa939953
 
Yogi Goddess Pres Conference Studio Updates
LDMMia Reiki Lectures
 
Trump Administration's workforce development strategy
Mebane Rash
 
Anesthesia in Laparoscopic Surgery in India
mohitsuren827
 
Microbial disease of the cardiovascular and lymphatic systems
KeyaSharma
 
The Lost Whites of Pakistan by Jahanzaib Mughal.pdf
jahanzaibmughal6
 
PPT- ENG7_QUARTER1_LESSON1_WEEK1. IMAGERY -DESCRIPTIONS pptx.pptx
KMDee
 
Cell Types and Its function , kingdom of life
ClaireMangundayao1
 
Chinmaya Tiranga quiz Grand Finale.pdf
Nitin Suresh
 
GDM (1) (1).pptx small presentation for students
shrawanbpkihs
 
A systematic review of self-coping strategies used by university students to ...
CleeveMoralde1
 
Pharma ospi slides which help in ospi learning
rameetkumar304
 
Computing-Curriculum for Schools in Ghana
abigailanane203
 
Chapter 2 Heredity, Prenatal Development, and Birth.pdf
MarjorieLopezTiu
 
RTP_AR_KS1_Tutor's Guide_English [FOR REPRODUCTION].pdf
RobertMentino1
 
2.FourierTransform-ShortQuestionswithAnswers.pdf
Raji Murugan
 
Orientation - ARALprogram of Deped to the Parents.pptx
JeromeTamayoSantiago1
 
STATICS OF THE RIGID BODIES Hibbelers.pdf
pascualasturiaskaye4
 
Tissue processing ( HISTOPATHOLOGICAL TECHNIQUE
mathiasmelwyn7
 
Ad

PMDT Guidelines and management strategies

  • 1. PMDT PART 2 Dr. G Nishanth Kumar Junior Resident Resp.Medicine,PIMS
  • 2. INDEX •BPal regimen •(H) mono/poly DR-TB regimen •Adverse drug events •Management of adverse drug events
  • 3. BPal regimen • Bedaquiline, Pretomanid, Linezolid (BPaL) regimen • Useful for MDR-TB with additional FQ resistance • New WHO recommendations • A treatment regimen lasting 6-9 months, composed of Bedaquiline, pretomanid and linezolid (BPaL) may be used under operational research conditions in MDR-TB patients with TB that is resistant to fluoroquinolones, who have either no previous exposure to Bedaquiline and linezolid or have been exposed for no more than 2 weeks; and • This is a new recommendation for a defined patient group; it is to be used under operational research conditions, and thus does not apply to routine programmatic use.
  • 4. • Evidence (Conradie F, et al NEJM. 2020 Mar 5;382(10):893-902 (Nix TB trial)): BPaL showed 90% favourable outcomes among XDR (89%), MDR with FQ resistance, treatment intolerant /non responders (92%); • Peripheral neuropathy 81%, myelosupression 48%, all managed often with dose reductions or interruptions in treatment with linezolid. Dosage & duration • Pretomanid - 200 mg once daily for 26 weeks, Bedaquiline - 400 mg once daily for the first 2 weeks of treatment (days 1–14) and then 200 mg three times a week for 24 weeks, and linezolid - 1200 mg once daily for 24 weeks (after 1 month, dose and duration modification for linezolid is permissible), with an option to extend treatment to 39 weeks if they were culture-positive at week 16.
  • 5. NTEG recommendation • BPaL research proposal may be considered with flexibility to adapt with anticipated results of ZeNix trial with 4 arms of reduce dosage and duration of Linezolid in BPaL; • and In exceptional cases, BPaL can be considered as a last resort by NTEP under prevailing ethical standards in individual patients for whom the design of an effective regimen is not possible as per WHO recommendations
  • 6. Implementation considerations • Pretomanid is approved by DCGI for use as part of BPaL regimen for conditional access under NTEP;In exceptional cases where an effective longer oral M/XDR-TB regimen cannot be designed with available drugs, NDR-TBC/state DT3C may send their case to national DT3C for clinical decision support and recommendations for BPaL; • Initial hospitalization for 15 days at NDR-TBC ward is necessary to closely monitor tolerability;
  • 7. (H) mono/poly DR-TB regimen • Once the patient is found to be rifampicin sensitive, the second specimen available must be sent immediately by the NAAT technician to the C&DST laboratory for FL-LPA test • The patient is immediately initiated on standard regimen for DS-TB by the concerned CHO at HWC/ health facility doctor or private health- care provider. • If H resistance is not detected, the patient will be continued on DS TB regimen and monitored for response to treatment.
  • 8. • If H resistance is detected on FL-LPA (serves as a surrogate of first-line poly resistance as per NDRS), the LPA deposit must be subjected to SL-LPA and LC&DST to Mfx, Z, Lzd, Cfz* and the test result must simultaneously be uploaded by a microbiologist at the C&DST lab on Nikshay • If H mono/poly DR-TB is detected, appropriate clinical evaluation is conducted by the treating doctor and H mono/poly DR-TB regimen is initiated at the respective health facility itself while waiting for the results of SL-LPA and LC&DST
  • 9. • As soon as the results of SL-LPA and LC&DST are available, the treating doctor may need to modify the regimen using the replacement sequence detailed later in the event of additional resistance or intolerance or non-availability of any drug in use or emergence of exclusion criteria • At any time during the treatment with DS-TB or H mono/poly DR-TB regimen with or without modifications, if there are signs of non- response, the patient must be subjected to NAAT again to rule out amplification of rifampicin resistance and further LPA and DST at specific time points
  • 11. Pre-treatment evaluation Pre-treatment evaluation for any TB patient must include a thorough clinical evaluation by a doctor with History and physical examination 1. Height/weight 2. Random blood sugar (RBS) 3. Chest X-ray 4. HIV test • No additional investigations are required for H mono/poly DR-TB patients unless clinically indicated
  • 12. H mono/poly DR-TB regimen (R resistance not detected & H resistance detected) under NTEP: • H mono/poly DR-TB regimen is of 6 or 9 months with no separate IP/CP. • In exceptional situations of unavailability of loose drug R or E or Z, the use of 4 FDC (HREZ) with Lfx loose tablets may be considered as an option rather than not starting the H mono/poly DR-TB patients on treatment.
  • 13. Treatment extension • Total duration of H mono/poly DR-TB regimen is 6 months. It can be extended directly to 9 months in certain conditions. • In patients with extensive disease; uncontrolled comorbidity; extra- pulmonary TB; if smear at the end of month 4 is found positive and when regimen is modified, the treatment may be directly extended to 9 months. There would be no monthly extensions in this regimen. • In patients who remain sputum smear positive at the end of month 5 or later, the treatment outcome will be declared as ‘treatment failed’ and the patient will be re-evaluated as per the diagnostic algorithm as a non-responder
  • 14. REPLACEMENT SEQUENCE • Treatment duration of H mono/poly DR-TB regimen can be longer in extensive pulmonary TB diseases up to 9 months
  • 17. • The most important evidence of response to DR-TB treatment is conversion of sputum smear and culture to negative. • Good quality sputum specimen is therefore essential to get reliable results that form the basis of monitoring bacteriological response to treatment. • It must be noted that the final treatment outcome of H mono/poly DR-TB patients will be declared based on follow up culture results.
  • 18. • NAAT, FL LPA, SL LPA (R, Eto, Lfx, Mfx) on fresh specimen and LC&DST (Mfx, Z, Lzd, Cfz*) (*whenever available) will be set up on the LPA deposits only for if patient remains smear/culture positive at end of month 4 and beyond if the patient has not reached bacteriological reversion. • If any change is required in the composition of H mono/poly DR-TB regimen due to the reason like resistance, intolerability, unavailability or contraindication during initial 4 months of treatment, re- initiation or re-registration is not required and patient will be continued • Long-term follow-up will be done with 6 monthly cultures among symptomatic patients till two years after completion of any DR-TB regimen i.e. months 6, 12, 18 and 24 post treatment.
  • 19. SPECIAL SITUATIONS 1) Pregnancy & Lactation • In pregnant women, the H mono/poly DR-TB regimen may be started or continued. • In women of reproductive age, treated for H mono/poly DR-TB, the use of rifampicin may interacts with contraceptives, resulting in decreased efficacy of protection against pregnancy. 2) Patients with extensive disease • The prolongation of the H mono/poly DR-TB regimen to more than 6 months could be considered on an individual basis for patients with extensive disease up to a maximum of 12 months.
  • 20. 3) People living with HIV • The H mono/poly DR-TB regimen is recommended in HIV reactive TB patients. • In TB patients with HIV coinfection, the first priority is to ensure that they are started on ART within 8 weeks of TB treatment initiation (regardless of CD4 count). This applies to H mono/poly DR-TB patients as well. 4)Extra-pulmonary disease • The treatment of patients with extra-pulmonary TB should be designed in close consultation with appropriate specialists (e.g. infectious disease physicians and neurologists), to decide upon individual variations in treatment duration and supportive care as needed. • In CNS, skeletal and miliary TB, treatment may be given up to a year.
  • 21. ADVERSE DRUG REACTIONS & THEIR MANAGEMENT
  • 25. 2)RASH, ALLERGIC REACTIONS & ANAPHYLAXIS • Suspected agent (s): Any drug • For minor dermatologic reactions, various agents can be helpful. In this case medication must be continued. • This could include antihistamines, hydrocortisone cream for localized rash, prednisone in a low dose of 10 to 20 mg per day for several weeks if other measures are not helpful and phototoxicity (may respond to sunscreens but can also cause rash).
  • 26. • Dry skin may cause itching (especially in diabetics). In which case, a liberal use of moisturizing lotion is recommended, since dry skin is a common and significant problem with Cfz. • Once rash resolves, reintroduce remaining drugs, one at a time with the one most likely to cause the reaction last. The order of reintroduction will be H, Z, Eto, E, FQ. • For serious allergic reactions, it will be important to stop all therapies pending resolution of reaction and refer the patient to Nodal DR-TB centre/ tertiary centre for further management
  • 27. 3) (i)Gastrointestinal symptoms (nausea and vomiting) • Suspected agent(s): Eto, PAS, Z, E, Bdq • Initiate the following 3-step approach to manage nausea and vomiting: Step 1. Adjust medication and conditions without lowering overall dose. Give Eto at night; Eto or PAS twice or thrice daily; light snack (biscuits, bread, rice, tea) before medication; and PAS two hours after other anti-TB drugs. Step 2. Start antiemetic(s) like metoclopramide 10 mg, 30 minutes before anti- TB medication; Ondansetron 8 mg, 30 minutes before anti-TB drugs and again eight hours after. Ondansetron can either be used on its own or with metoclopramide (if ondansetron is not available, promethazine can be used). For refractory nausea give 24 mg, 30 minutes before the dose. Step 3. Decrease dose of suspected drug by one weight class (except Bdq and Dlm) if this can be done without compromising the regimen. It is rarely necessary to suspend the drug completely.
  • 28. 3)(ii) Gastrointestinal symptoms (gastritis & abdominal pain) • Suspected agent(s): PAS, Eto, Cfz, Lzd, FQs, H, E, and Z • if symptoms are associated and consistent with gastritis (epigastric burning or discomfort, sour taste in mouth associated with reflux) initiate medical treatment with the use of H2-blockers (ranitidine 150 mg twice daily or 300 mg once daily) better than proton-pump inhibitors (omeprazole 20 mg once daily) which should be avoided along with Bdq. • Avoid use of antacids as they decrease absorption of FQ; for severe abdominal pain, stop suspected agent(s) for short periods of time (1–7 days); lower the dose of the suspected agent, if this can be done without compromising the regimen; and discontinue suspected agent if this can be done without compromising the regimen
  • 29. 4)Hepatitis • Suspected agent(s): Z, H, R, Eto, PAS, Bdq
  • 31. 5)Giddiness • Suspected agent (s) – Am, Eto, FQ and/or Z • Aminoglycosides, especially in elderly age group must be kept in mind for giddiness as it may be early sign of 8th nerve toxicity 6) Haematological abnormalities • Stop Lzd if myelosuppression (suppression of white blood cells, red blood cells or platelets) occurs. • Consider restarting with a lower dose of Lzd (300 mg instead of 600 mg) if myelosuppression resolves and if Lzd is considered essential to the regimen. • Consider nondrug related causes of hematological abnormality. • Consider blood transfusion for severe anemia.
  • 32. 7)Arthralgia • Suspected agent(s): Z, FQ, Bdq • Initiate with paracetamol in the beginning. • Treatment with nonsteroidal anti-inflammatory drugs (indomethacin 50 mg twice daily or ibuprofen 400 to 800 mg three times a day). • Lower the dose of the suspected agent (most commonly Z) if this can be done without compromising the regimen. • Discontinue the suspected agent if this can be done without compromising the regimen.
  • 33. 8)Peripheral neuropathy • Suspected agent(s): Lzd, Cs, H, Am, FQ, rarely Eto, E • To prevent occurrence of such adverse reaction, all patients on an NTEP regimen for MDRTB should receive daily pyridoxine. • The commonest offending agent is Lzd, almost 60–70% of the patients on Lzd 600 mg/day may develop neuropathy and pyridoxine does not help in preventing Lzd induced neuropathy. • Early recognition of neuropathy symptoms and early dose reduction of Lzd helps to prevent the progression. • If there is no improvement or symptoms worsen,amitriptyline 25mg will be added (to be avoided with Bdq) and if there is still no improvement, the patient should be referred to a neurologist; • correct any vitamin or nutritional deficiencies and maximum daily dose (100 mg/day);consider whether the dose of Cs can be reduced without compromising the regimen. If H is being used (especially Hh), consider stopping it
  • 34. 9)Depression, psychotic & suicidal ideation • Stop the suspected agent for a short period (1–4 weeks) while psychotic symptoms are brought under control. • The most likely drug is Cs followed Hh .If moderate to severe symptoms persist, initiate antipsychotic treatment (haloperidol).Hospitalize in a ward with psychiatric expertise if patient is at risk to himself/herself or others. • Lower the dose of the suspected agent (if it can be done without compromising the regimen).Discontinue suspected agent if this can be done without compromising the regimen
  • 35. 10)Seizures • Suspected agent(s): Cs, H, FQ • Hold Cs, FQ and H pending resolution of seizures. Initiate anticonvulsant treatment –carbamazepine, phenytoin or valproic acid (relatively safe with Bdq) are most commonly used. 11)Tendonitis and tendon rupture • Suspected agent(s): FQ • If significant inflammation of tendons or tendon sheaths occur, consider stopping FQ. • Give a non-steroidal anti-inflammatory drug (ibuprofen 400 mg four times daily).Rest the joint. • if treatment failed is likely without FQ: reduce dose if possible ensure joint is strictly rested inform patient of the possible risk of tendon rupture and discuss the risks and benefits of ongoing use of FQ
  • 36. 12) Nephrotoxicity (renal toxicity) • Suspected agent(s): Am • Discontinue the suspected agent. Consider using Cm if an aminoglycoside had been the prior injectable drug in the regimen. • Consider other contributing etiologies (non-steroidal anti- inflammatory drugs, diabetes, other medications, dehydration, congestive heart failure, urinary obstruction, etc.,) and address as indicated. • Follow creatinine (and electrolyte) levels closely, every 1–2 weeks.Consider dosing the injectable agent 2–3 times a week if the drug is essential to the regimen and the patient can tolerate (close monitoring of creatinine). • If creatinine continues to rise despite twice/thrice a week dosing, suspend the injectable agent.Adjust all TB medication according to creatinine clearance in consultation with nephrologist. • Also, note that renal impairment may be permanent.
  • 37. 13)Vestibular toxicity (tinnitus and dizziness) • Suspected agent(s): Am, Cs, FQs, H, Eto, Lzd • If early symptoms of vestibular toxicity appear, there may be a need to change dosing of the injectable agent to twice/thrice a week. • Also, consider using Cm if an aminoglycoside had been the prior injectable in the regimen. If tinnitus and unsteadiness worsen with the above adjustment, stop the injectable agent. • This is one of the few adverse events that may cause permanent intolerable toxicity and can necessitate discontinuation of a class of agents
  • 38. 14)Hearing loss • Suspected agent(s): Am • Common cause is aminoglycosides if the reason like wax and middle ear infection is ruled out. • Document hearing loss and compare with baseline audiogram if available (some degree of hearing loss occurs with most patients starting with high frequency loss). • If early symptoms of hearing loss are documented, change dosing of the injectable agent to twice/thrice a week. • Discontinue injectable agent if hearing loss continues despite dose adjustment and add additional drugs to reinforce the regimen. • Even when additional drugs are not available, stopping the injectable agent can be considered based on the patient’s desire to maintain hearing.
  • 39. 15) Optic neuritis • Suspected agent(s): E, Lzd, Eto, Cfz, H, S • Stop E and Lzd. Do not restart. • Refer patient to an ophthalmologist. 16)Metallic taste • Suspected agent(s): Eto, FQs • Suggested management strategy: Encourage the patient to tolerate this side effect.
  • 40. 17)Electrolyte disturbances- hypokalaemia and hypomagnesaemia • Suspected agent(s): Am • Evaluate potassium levels. • If potassium is low, check for magnesium and calcium (if unable to check for magnesium, consider empiric treatment with magnesium in all patients of hypokalaemia). • Replace electrolytes as needed. • Dose oral electrolytes apart from FQ as they can interfere with FQ absorption. • Manage electrolyte disturbances.
  • 41. 18)Gynaecomastia • Suspected agent(s): Eto • Breast enlargement can be a troublesome side effect of Eto treatment, especially for male patients. • Galactorrhoea has also been reported.Encourage patients to tolerate this side effect 19)Alopecia • Suspected agent(s):H, Eto • hair loss can occur or there can be significant thinning of the hair, but this is temporary and not progressive during treatment. • Encourage patients to tolerate this side effect.
  • 42. 20)Superficial fungal infection and thrush • Suspected agent(s): FQ • Topical antifungal agents or short course oral antifungal drugs are helpful. Exclude other diseases if response to treatment is not prompt (such as HIV). 21)Lactic acidosis • Suspected agent(s): Lzd • Suggested management strategy: Stop Lzd if lactic acidosis occurs
  • 45. Treatment outcome of DR-TB Interim outcomes 1. Bacteriological conversion. After bacteriological confirmation of TB at least two consecutive cultures (applicable for DR-TB and DS-TB) or smears taken on different occasions at least 7 days apart (applicable for DS-TB only) are found to be negative. 2. Bacteriological reversion. At least two consecutive cultures (applicable for DR-TB and DSTB) or smears (applicable for DS-TB only) taken on different occasions at least 7 days apart are found to be positive either after the initial conversion or for patients without bacteriological confirmation of TB
  • 46. FINAL OUTCOMES • Treatment failed. A patient whose treatment regimen needs to be terminated or permanently changed to a new regimen option or treatment strategy. • Cured. A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national policy with evidence of bacteriological response and no evidence of treatment failed.
  • 47. • Treatment completed. A patient who completed treatment as recommended by the national policy whose outcome does not meet the definition for cure or treatment failed. • Died. A patient who died before starting or during the course of treatment. • Lost to follow-up. A patient who did not start treatment or whose treatment was interrupted for 2 consecutive months or more. • Not evaluated. A patient for whom no treatment outcome was assigned4
  • 48. TPT among contacts of DR-TB patients
  • 49. • WHO recommends TPT among contacts exposed to MDR-TB with FQ sensitive or H resistant with R sensitive DR-TB patients following consideration of intensity of exposure; confirming the source patient and her/his drug resistance pattern confirmed bacteriologically and ascertaining TBI using IGRA or TST. • Among contacts exposed to patients with known MDR-TB with FQ sensitive, WHO suggests the use of levofloxacin for six months (pediatric formulation for child contacts) if tolerated.
  • 50. • If H susceptibility is confirmed in RR-TB index patients, contacts may be given 6H. • Among contacts exposed to individuals with known H-resistant TB with R sensitive, the use of rifampicin for four months is proposed. • Regardless of whether treatment is given or not, clinical followup should be done for two years and any emergent signs and symptoms suggestive of TB should be actively investigated and curative regimens started as needed.
  • 52. Policy for TPT in DR-TB contacts in India • Preventive treatment among HHC of MDR-TB index patients (in whom FQ resistance has been ruled out) and among HHC of H resistant index patients (in whom R resistance has been ruled out), the target population, using 6Lfx and 4R respectively to be introduced in a phased manner for all age groups to gain programmatic experience to guide future expansion while awaiting results of ongoing studies. • This recommendation may be considered for children given their special needs pan-India.